The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
7 citations
,
September 2024 in “Journal of Comparative Effectiveness Research” Palbociclib generally maintains or improves quality of life in advanced breast cancer patients.
1 citations
,
August 2024 in “Indian Dermatology Online Journal” Bicalutamide may effectively treat female pattern hair loss with minimal side effects.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
19 citations
,
May 2014 in “Molecules” Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.
September 2024 in “Indian Journal of Dermatology Venereology and Leprology” Mesotherapy with bicalutamide has limited effectiveness for female hair loss.
October 2025 in “Actas Dermo-Sifiliográficas” RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
September 2019 in “Journal of Investigative Dermatology” Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
January 1983 in “Elsevier eBooks” Cyproterone acetate is used to treat conditions like prostate cancer, early puberty, excessive sexual drive, and female androgenization by affecting androgen functions and suppressing certain hormones.
2 citations
,
March 2025 in “ESMO Open” Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib significantly improves hair regrowth in severe alopecia areata.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
11 citations
,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
January 2023 in “International Journal of Trichology” Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.
36 citations
,
October 2009 in “Journal of biological chemistry/The Journal of biological chemistry” Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
May 1993 in “Drugs & Therapy Perspectives” Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
January 2026 in “Journal of Ethnopharmacology” Cedrol promotes hair growth better than baricitinib by regulating immune cells.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
4 citations
,
November 2021 in “Journal of The American Academy of Dermatology” Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”